Administration of CD4+CD25highCD127−FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study

Chwojnicki, Kamil; Iwaszkiewicz-Grześ, Dorota; Jankowska, Anna; Zieliński, Maciej; Łowiec, Paweł; Gliwiński, Mateusz; Grzywińska, Małgorzata; Kowalczyk, Kamil; Konarzewska, Aleksandra; Glasner, Paulina; Sakowska, Justyna; Kulczycka, Julia; Jaźwińska-Curyłło, Anna; Kubach, Marlena; Karaszewski, Bartosz; Nyka, Walenty M.; Szurowska, Edyta; Trzonkowski, Piotr

doi:10.1007/s40259-020-00462-7

Cited by 36 publications

(27 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the context of therapeutic tolerance induction, the activation and expansion of Tregs is critical for actively controlling autoreactive T cells against multiple antigens. A phase Ib/IIa using autologous Tregs in MS patients has been reported recently with good safety results (30). Different from the above elimination of autoreactive T cells by apoptosis or silencing by anergy, Treg-mediated tolerance is expected to last long(er) and be able to control a broader range of autoreactive T cells.…”

Section: S98-s100mentioning

confidence: 99%

Antigen-Specific Immune Tolerance in Multiple Sclerosis—Promising Approaches and How to Bring Them to Patients

et al. 2021

View full text Add to dashboard Cite

Antigen-specific tolerance induction aims at treating multiple sclerosis (MS) at the root of its pathogenesis and has the prospect of personalization. Several promising tolerization approaches using different technologies and modes of action have already advanced to clinical testing. The prerequisites for successful tolerance induction include the knowledge of target antigens, core pathomechanisms, and how to pursue a clinical development path that is distinct from conventional drug development. Key aspects including patient selection, outcome measures, demonstrating the mechanisms of action as well as the positioning in the rapidly growing spectrum of MS treatments have to be considered to bring this therapy to patients.

show abstract

Section: S98-s100mentioning

confidence: 99%

Antigen-Specific Immune Tolerance in Multiple Sclerosis—Promising Approaches and How to Bring Them to Patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…(trial registration: EudraCT: 2014-004320-22. 94 The therapy proved to be safe. Although very preliminary, the results also suggested that intrathecal administration was more effective than intravenous administration.…”

Section: Cell-based Tolerogenic Therapiesmentioning

confidence: 97%

“…The main regulatory mechanism of pTregs involves the secretion of suppressive factors such as IL-10, produced mainly by Tr1 cells, or TGF-β, produced by Th3 cells. 92 , 94 Currently, tTregs are the main subset used in the clinic, but a limited number of trials using Tr1 cells have also been conducted.…”

Section: Cell-based Tolerogenic Therapiesmentioning

confidence: 99%

“…Experiments with adoptive transfer of Tregs suggested the good safety profile of Tregs administered via both tested routes. 94 …”

Section: Cell-based Tolerogenic Therapiesmentioning

confidence: 99%

“…The patients did not experience relapse, and MRI confirmed stable nonprogressing lesions in the CNS of these patients, which proved that this approach should be further tested in future trials. 94 …”

Section: Cell-based Tolerogenic Therapiesmentioning

confidence: 99%

See 2 more Smart Citations

Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy

et al. 2021

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the disease and have the potential to cause serious adverse events. Hence, there is an urgent need for the development of next-generation treatments that, alone or in combination, stop the undesired autoimmune response and contribute to the restoration of homeostasis. This review analyzes current MS treatments as well as different cell-based therapies that have been proposed to restore homeostasis in MS patients (tolerogenic dendritic cells, regulatory T cells, mesenchymal stem cells, and vaccination with T cells). Data collected from preclinical studies performed in the experimental autoimmune encephalomyelitis (EAE) model of MS in animals, in vitro cultures of cells from MS patients and the initial results of phase I/II clinical trials are analyzed to better understand which parameters are relevant for obtaining an efficient cell-based therapy for MS.

show abstract

Role of regulatory T cells in pathogenesis and therapeutics of Crohn’s disease and ulcerative colitis

Weerakoon,

Lepletier

2024

Regulatory T Cells and Autoimmune Diseases

View full text Add to dashboard Cite

Administration of CD4+CD25highCD127−FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study

Cited by 36 publications

References 39 publications

Antigen-Specific Immune Tolerance in Multiple Sclerosis—Promising Approaches and How to Bring Them to Patients

Antigen-Specific Immune Tolerance in Multiple Sclerosis—Promising Approaches and How to Bring Them to Patients

Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy

Role of regulatory T cells in pathogenesis and therapeutics of Crohn’s disease and ulcerative colitis

Contact Info

Product

Resources

About